Prime Medicine Q2 EPS $(0.46) Misses $(0.41) Estimate
Portfolio Pulse from Benzinga Newsdesk
Prime Medicine (NASDAQ:PRME) reported a Q2 EPS of $(0.46), missing the analyst consensus estimate of $(0.41) by 12.2%. This represents a 2.13% improvement over the $(0.47) loss per share from the same period last year.
August 08, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Prime Medicine reported a Q2 EPS of $(0.46), missing the analyst consensus estimate of $(0.41) by 12.2%. Despite the miss, the loss per share improved by 2.13% compared to the same period last year.
The miss on EPS estimates by 12.2% is likely to negatively impact the stock price in the short term. However, the slight improvement in losses compared to the previous year may provide some cushion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100